Skip to content

Radiotherapy in COVID-19

Assessment of adding low dose pulmonary radiotherapy to the national protocol of COVID-19 management: A pilot trial.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200509047366N1
Enrollment
5
Registered
2020-05-12
Start date
2020-05-21
Completion date
Unknown
Last updated
2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia. Pneumonia due to SARS-associated coronavirus

Interventions

Intervention group: Low dose RT.

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to No maximum

Inclusion criteria

Inclusion criteria: Confirmed COVID-19 diagnosis ( PCR or serologic) Presence of pulmonary involvement ( defined by P/F ratio or NIV need) Less than 3 days since the onset of ARDS Age > 60 years ? IL-6 ( if available) ? CRP

Exclusion criteria

Exclusion criteria: Lack of informed consent Inability to transfer to the radiation unit Hemodynamic instability Septic shock and organ dysfunction Severe ARDS P/F ratio = 100 mmHg History of cardiac failure Contraindications to radiation

Design outcomes

Primary

MeasureTime frame
Increase in arterial oxygen pressure. Timepoint: day 1,2,3,4,5,6,7,14,21,28 post treatment. Method of measurement: Blood sample.

Secondary

MeasureTime frame
P/F ratio. Timepoint: day 1,2,3,4,5,6,7,21,28. Method of measurement: Blood gas analysis.;Hs-CRP. Timepoint: day 1,2,3,4,5,6,7,21,28. Method of measurement: blood sample.;IL-6 serum level. Timepoint: day 1,4,7,21,28. Method of measurement: blood sample.;ESR. Timepoint: day 1,2,3,4,5,6,7,14,21,28. Method of measurement: Blood sample.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazanin Rahnama

Shahid Beheshti University of Medical Sciences

Nazanin.rahnama@sbmu.ac.ir+98 21 2273 1056

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026